Y-mAbs Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results an issued FY24 total net revenue guidance with its midpoint below estimates.
Portfolio Pulse from Benzinga Newsdesk
Y-mAbs Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results and issued FY24 total net revenue guidance with its midpoint below estimates.
August 12, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Y-mAbs Therapeutics reported worse-than-expected Q2 financial results and issued FY24 total net revenue guidance with its midpoint below estimates, leading to a drop in share price.
The company's disappointing Q2 results and lower-than-expected FY24 revenue guidance are likely to negatively impact investor sentiment and lead to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100